HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More toothpaste with DEG

This article was originally published in The Tan Sheet

Executive Summary

U.S. Customs and Border Protection officers in Charleston, S.C. seized 1,440 tubes of toothpaste adulterated with antifreeze ingredient diethylene glycol, agency announces Oct. 5. The toothpaste had deceptive country of origin markings on packaging - the boxes were marked "made in India," while shrink wrap housing the boxes were marked "made in China," CBP notes. Officers performed an initial examination of the shipment in July and sent samples to a lab where they tested positive for DEG. In June China ordered the detention without physical examination of all dentifrice products including aerosols, liquids, toothpastes and tooth powders with or without fluoride containing DEG after FDA discovered the ingredient in several Chinese-manufactured products. China has also banned firms from using DEG as a toothpaste ingredient (1"The Tan Sheet" July 16, 2007, p. 9)...

You may also be interested in...



China Bans Using DEG In Toothpaste, But Denies Possible Health Problem

A month after saying levels of diethylene glycol found in toothpaste imported from China do not cause health problems, China has banned firms in the country from using DEG as a toothpaste ingredient, citing bans by the U.S. and other countries on sales of toothpaste products containing the chemical

Joint Mission: FDA And VA Partner On Device Development Initiative

The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.

Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch

With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS138329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel